PT  - JOURNAL ARTICLE
AU  - Porcu, Eleonora
AU  - Sadler, Marie C.
AU  - Lepik, Kaido
AU  - Auwerx, Chiara
AU  - Wood, Andrew R.
AU  - Weihs, Antoine
AU  - Ribeiro, Diogo M.
AU  - Bandinelli, Stefania
AU  - Tanaka, Toshiko
AU  - Nauck, Matthias
AU  - Völker, Uwe
AU  - Delaneau, Olivier
AU  - Metspalu, Andres
AU  - Teumer, Alexander
AU  - Frayling, Timothy
AU  - Santoni, Federico A.
AU  - Reymond, Alexandre
AU  - Kutalik, Zoltán
TI  - Differentially expressed genes reflect disease-induced rather than disease-causing changes in the transcriptome
AID  - 10.1101/2020.10.19.20213538
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.19.20213538
4099  - http://medrxiv.org/content/early/2020/10/21/2020.10.19.20213538.short
4100  - http://medrxiv.org/content/early/2020/10/21/2020.10.19.20213538.full
AB  - Comparing transcript levels between healthy and diseased individuals allows the identification of differentially expressed genes, which may be causes, consequences or mere correlates of the disease under scrutiny. Here, we propose a bi-directional Transcriptome-Wide Mendelian Randomization (TWMR) approach that integrates summary-level data from GWAS and whole-blood eQTLs in a MR framework to investigate the causal effects between gene expression and complex traits.Whereas we have previously developed a TWMR approach to elucidate gene expression to trait causal effects, here we are adapting the method to shed light on the causal imprint of complex traits on transcript levels. We termed this new approach reverse TWMR (revTWMR). Integrating bi-directional causal effects between gene expression and complex traits enables to evaluate their respective contributions to the correlation between gene expression and traits. We uncovered that whole blood gene expression-trait correlation is mainly driven by causal effect from the phenotype on the expression rather than the reverse. For example, BMI- and triglycerides-gene expression correlation coefficients robustly correlate with trait-to-expression causal effects (r=0.09, P=1.54×10−39 and r=0.09, P=1.19×10−34, respectively), but not detectably with expression-to-trait effects.Genes implicated by revTWMR confirmed known associations, such as rheumathoid arthritis and Crohn’s disease induced changes in expression of TRBV and GBP2, respectively. They also shed light on how clinical biomarkers can influence their own levels. For instance, we observed that high levels of high-density lipoprotein (HDL) cholesterol lowers the expression of genes involved in cholesterol biosynthesis (SQLE, FDFT1) and increases the expression of genes responsible for cholesterol efflux (ABCA1, ABCG1), two key molecular pathways in determining HDL levels. Importantly, revTWMR is more robust to pleiotropy than polygenic risk score (PRS) approaches which can be misled by pleiotropic outliers. As one example, revTWMR revealed that the previously reported association between educational attainment PRS and STX1B is exclusively driven by a highly pleiotropic SNP (rs2456973), which is strongly associated with several hematological and anthropometric traits.In conclusion, our method disentangles the relationship between gene expression and phenotypes and reveals that complex traits have more pronounced impact on gene expression than the reverse. We demonstrated that studies comparing the transcriptome of diseased and healthy subjects are more prone to reveal disease-induced gene expression changes rather than disease causing ones.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Swiss National Science Foundation (310030-189147, 32473B-166450 to ZK and 31003A_182632 to AR) and Horizon2020 Twinning projects (ePerMed 692145 to AR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the data used in this study are publicly available. https://www.eqtlgen.org https://grasp.nhlbi.nih.gov/FullResults.aspx The Estonian Genome Center, University of Tartu data was used under data application nr 3-10/GV-18964-280915, regulation nr 3-12.4/GV-00058. Approval was obtained from the Research Ethics Committee of the University of Tartu. All study participants have signed a broad informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are publicly available. https://www.eqtlgen.org https://grasp.nhlbi.nih.gov/FullResults.aspx. No application for access nor registration was required to access the data from eQTLGen and GRASP